New Preclinical Data on BTX-A51 in Liposarcoma Models to be Highlighted at AACR Annual Meeting 2025
BROOKLINE, Mass—April 16, 2025--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced the upcoming presentation of new preclinical data from studies of BTX-A51 in human liposarcoma conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School. These data will be featured in poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, Illinois.
The presentations will showcase the therapeutic potential of BTX-A51, a first-in-class dual inhibitor of casein kinase 1 alpha (CK1a) and cyclin-dependent kinases 7 and 9 (CDK7/9), in preclinical models of human liposarcoma and CIC-rearranged sarcoma—a rare and aggressive cancer that tends to affect pediatric and younger adult patients.
Presentation Details:
Poster 1:
Title: Therapeutic Potential of Combined Targeting of Casein Kinase 1 alpha (CK1 alpha) and CDK7/9 with the Inhibitor BTX-A51 in Human Liposarcomas
Session Category: Experimental and Molecular Therapeutics
Session Title: Identification of Molecular Targets 1
Date and Time: Monday, April 28, 2025 | 2:00 PM – 5:00 PM CT
Location: Poster Section 19 | Board Number: 10
Abstract Number: 2980
These data support the ongoing phase 1 study of BTX-A51 in patients with advanced MDM2-amplified liposarcoma. Additional details about the study can be found at clinicaltrials.gov under the identifier NCT06414434.
Poster 2:
Title: Preclinical efficacy of the CK1 alpha/CDK7/CDK9 inhibitor BTX-A51 in CIC-rearranged sarcoma
Session Category: Experimental and Molecular Therapeutics
Session Title: Protein Kinases and Phosphatases as Targets for Therapy
Date and Time: Wednesday, April 30, 2025 | 9:00 AM – 12:00 PM CT
Location: Poster Section 24 | Board Number: 3
Abstract Number: 6941
About Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. BTX-A51 is a novel small molecule, multi-kinase inhibitor that synergistically co-targets master regulators of cancer to activate programmed cell death, or apoptosis. BTX-A51 holds promise in acute myeloid leukemia and genetically-defined solid tumors, which are the focus of ongoing clinical programs. For more information, please visit www.edgewoodoncology.com, and follow us on LinkedIn.
Contact
Tracy Lessor
TLOW Communications, LLC
617-519-9827